328 related articles for article (PubMed ID: 14595048)
1. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life.
Tozzi AE; Ravà L; Ciofi degli Atti ML; Salmaso S;
Pediatrics; 2003 Nov; 112(5):1069-75. PubMed ID: 14595048
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
4. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
[TBL] [Abstract][Full Text] [Related]
5. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
[TBL] [Abstract][Full Text] [Related]
6. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group.
Salmaso S; Mastrantonio P; Wassilak SG; Giuliano M; Anemona A; Giammanco A; Tozzi AE; Ciofi degli Atti ML; Greco D
Vaccine; 1998 Aug; 16(13):1270-5. PubMed ID: 9682390
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
10. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
11. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
Weigl JA; Bock HL; Clemens R; Zepp F; Habermehl P; Beutel K; Müschenborn S; Sümenicht G; Schuind A; von König CH; Neiss A; Laukamp S; Kiederle S; Schmitt HJ
Ann Acad Med Singap; 1997 May; 26(3):320-5. PubMed ID: 9285026
[TBL] [Abstract][Full Text] [Related]
13. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
14. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
[TBL] [Abstract][Full Text] [Related]
15. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
Cherry JD; Heininger U; Stehr K; Christenson P
Pediatrics; 1998 Oct; 102(4 Pt 1):909-12. PubMed ID: 9755264
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
17. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
18. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
19. Acellular vaccines for preventing whooping cough in children.
Zhang L; Prietsch SO; Axelsson I; Halperin SA
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD001478. PubMed ID: 25228233
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
Lugauer S; Heininger U; Cherry JD; Stehr K
Eur J Pediatr; 2002 Mar; 161(3):142-6. PubMed ID: 11998910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
